Delcath Systems (NASDAQ:DCTH) Upgraded to "Strong-Buy" at Wall Street Zen

Delcath Systems (NASDAQ:DCTH - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Separately, HC Wainwright restated a "buy" rating and set a $29.00 target price (up previously from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $24.00.

Delcath Systems Stock Up 0.6%

Shares of DCTH stock traded up $0.10 during trading hours on Friday, hitting $16.51. 169,704 shares of the company's stock traded hands, compared to its average volume of 373,037. The stock's fifty day simple moving average is $13.15 and its two-hundred day simple moving average is $13.05. Delcath Systems has a 12-month low of $6.33 and a 12-month high of $18.23. The stock has a market cap of $574.98 million, a price-to-earnings ratio of -12.20 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). The company had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. On average, equities analysts forecast that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors have recently made changes to their positions in the business. Quarry LP bought a new stake in shares of Delcath Systems during the 4th quarter valued at $34,000. Quantbot Technologies LP bought a new stake in shares of Delcath Systems during the 4th quarter valued at $66,000. Inlight Wealth Management LLC purchased a new stake in Delcath Systems in the 1st quarter worth $85,000. NBC Securities Inc. grew its position in shares of Delcath Systems by 99,900.0% during the first quarter. NBC Securities Inc. now owns 10,000 shares of the company's stock worth $127,000 after purchasing an additional 9,990 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in Delcath Systems during the 4th quarter valued at approximately $123,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.